Business Context and Reporting Period
Company: EUDA Health Holdings Ltd (EUDA)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: EUDA is a British Virgin Islands company operating primarily in property management services in Singapore and holistic wellness consumer products/services in Malaysia. In September 2023, the Company discontinued its medical services operations (classified as discontinued operations) to streamline costs. In May 2024, EUDA acquired CK Health Plus Sdn Bhd ("CK Health") to expand into the wellness sector, including bioenergy cabins and planned stem cell therapy distribution.
Key Financial Metrics (Fiscal Year 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Total Revenue | $4,011,005 | $3,706,458 |
| Net Loss | $(15,391,443) | $(10,036,104) |
| Net Loss from Continuing Operations | $(17,637,783) | $(8,434,781) |
| Net Income from Discontinued Operations | $2,246,340 | $(1,601,323) |
| Gross Profit | $762,155 | $842,075 |
| Operating Cash Flow (Continuing) | $(2,025,572) | $(3,213,862) |
| Cash and Cash Equivalents (Dec 31, 2024) | $237,605 | $189,005 |
| Working Capital Deficit | ~$3.4 million | ~$8.0 million |
| Outstanding Ordinary Shares | 37,153,049 | 24,627,509 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 8.2% to $4.01 million, driven by a 5.8% increase in property management services and the addition of $89,023 in revenue from the newly acquired CK Health wellness segment.
- Significant Impairment: Operating expenses surged due to a one-time impairment loss of $14.76 million on intangible assets acquired from Fortress Cove Limited (CK Health). This was recorded because the acquisition was treated as an asset purchase, and the fair value of assets was less than the consideration paid.
- Discontinued Operations: The Company recorded a net income of $2.25 million from discontinued operations in 2024, compared to a loss of $1.60 million in 2023, primarily due to a gain on the disposal of subsidiaries.
- Debt Settlements: The Company incurred a $448,000 loss on debt settlements in 2024, down from $645,612 in 2023, as it settled obligations with related parties and third parties via share issuances.
Guidance, Outlook, Risks, and Contingencies
Going Concern Uncertainty
The independent auditors (J&S Associate PLT) have issued an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern. This is due to recurring losses, a working capital deficit of approximately $3.4 million, and minimal cash on hand ($0.2 million). The Company requires additional financing to fund operations.
Strategic Outlook
Management is pivoting from medical services to the wellness industry. Key initiatives include:
- CK Health Expansion: Leveraging CK Health to sell wellness products, bioenergy cabins, and stem cell therapy packages (via a collaboration with Key Lock Health Management and Guangdong Cell Biotech).
- Stem Cell Therapy: Plans to market stem cell therapies in Singapore and Malaysia, though the Company has no direct experience in this line of business and relies on third-party treatment centers in China.
Material Risks
- Internal Controls: The Company identified a material weakness in internal controls over financial reporting related to account reconciliations. Management is developing a remediation plan.
- Related Party Dependence: The Company relies heavily on loans and convertible notes from related parties (e.g., 8i Enterprises Pte Ltd, Alfred Lim, Meng Dong Tan) to fund operations. Significant shareholders hold demand registration rights that could depress share prices upon resale.
- Acquisition Risks: There is no assurance that the CK Health acquisition will achieve desired financial benefits. The business model for CK Health remains unproven.
- Legal Proceedings: The Company is involved in disputes regarding director appointments and a statutory demand for legal fees ($138,202) from Carey Olsen Singapore LLP, which the Company contests.
Investor Verification Checklist
- Capital Raising Status: Verify if the Company has secured the necessary equity or debt financing to bridge the liquidity gap and avoid insolvency.
- Remediation of Internal Controls: Confirm the progress of the plan to remediate the material weakness in financial reporting to ensure future financial accuracy.
- CK Health Performance: Monitor the revenue generation and profitability of the CK Health subsidiary to validate the $15 million acquisition valuation.
- Stem Cell Regulatory Compliance: Assess the regulatory risks and operational viability of the new stem cell therapy distribution agreement in Singapore and Malaysia.
- Related Party Transactions: Review the terms of ongoing loans from related parties and the potential dilution from convertible notes and share settlements.